"Boron Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inorganic or organic compounds that contain boron as an integral part of the molecule.
| Descriptor ID |
D001896
|
| MeSH Number(s) |
D01.132 D02.203
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Boron Compounds".
Below are MeSH descriptors whose meaning is more specific than "Boron Compounds".
This graph shows the total number of publications written about "Boron Compounds" by people in this website by year, and whether "Boron Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 3 | 0 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 4 | 6 |
| 2017 | 0 | 3 | 3 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 3 | 3 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Boron Compounds" by people in Profiles.
-
Incorporating boron distribution variations in microdosimetric kinetic model-based relative biological effectiveness calculations for boron neutron capture therapy. Radiat Prot Dosimetry. 2024 Sep 10; 200(14):1319-1328.
-
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma. Am J Hematol. 2024 Sep; 99(9):1746-1756.
-
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 Apr 09; 8(7):1612-1620.
-
Reactive metal boride nanoparticles trap lipopolysaccharide and peptidoglycan for bacteria-infected wound healing. Nat Commun. 2022 11 29; 13(1):7353.
-
Effect of boron compounds on the biological effectiveness of proton therapy. Med Phys. 2022 09; 49(9):6098-6109.
-
Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. Clin Cancer Res. 2022 04 01; 28(7):1277-1284.
-
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase? 2 trial. Blood Cancer J. 2022 01 24; 12(1):9.
-
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Invest New Drugs. 2022 02; 40(1):99-105.
-
The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models. J Virol. 2021 05 24; 95(12).
-
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (=2nd relapse) refractory myeloma: a multicenter real world UK experience. Leuk Lymphoma. 2021 06; 62(6):1396-1404.